By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3-12-5 Shibaura, Ishizaka
Building 6F
Minato-ku  Tokyo  108-0023  Japan
Phone: 81-3-3456-0820 Fax:



Company News
REGiMMUNE Phase IIa Results Of RGI-2001, An Activator Of Invariant Natural Killer T Cells, Published In "Biology Of Blood And Marrow Transplantation" 3/10/2017 7:57:18 AM
REGiMMUNE Announces Collaboration With Juvenile Diabetes Research Foundation And Pfizer (PFE) For Type 1 Diabetes Prevention And Treatment Promoting Regulatory T-Cells 4/14/2015 11:25:43 AM
REGiMMUNE To Present Its Method For Long-Term Tolerance In Organ Transplantation At World Transplant Congress In San Francisco 7/28/2014 10:16:32 AM
REGiMMUNE Nabs $9.2 Million Series D Financing 2/14/2014 7:35:05 AM
REGiMMUNE Begins Enrollment For Phase II Clinical Trial For Graft Versus Host Disease 2/6/2014 9:34:01 AM
REGiMMUNE Initiates Phase I/II Clinical Trial for GvHD 2/1/2012 8:40:05 AM
REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress 5/5/2010 11:19:23 AM
REGiMMUNE to Present Data From Preclinical Study of RGI-2001 at the 2010 American Transplant Congress 4/28/2010 11:26:50 AM
Astellas Pharma Inc. and REGiMMUNE to Collaborate on New Vaccine Technology 7/22/2009 10:34:51 AM
REGiMMUNE Presents Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress 6/1/2009 11:12:47 AM